About Sure Steps™
Sure Steps is a supplemental education and support program for patients on Tracleer and their caregivers. Sure Steps is designed
to answer your general questions about pulmonary arterial hypertension (PAH)* and Tracleer® (bosentan). When you enroll in Sure
Steps, you'll receive—at no cost to you—education and tools to help you better manage your treatment with Tracleer.
Remember: Nothing can replace the advice and care of your healthcare team. Always consult them if you have questions or concerns
about your disease or your treatment with Tracleer.
As a Sure Steps member, here’s what you’ll get:
- Educational materials
- One-on-one phone support
- Sure Steps website access
- Sure Steps Connect™ access
- Caregivers can take part in Sure Steps too!
Educational materials
Information-packed communications and tools designed to help keep you motivated about your treatment with Tracleer. Includes:
- Educational mailings to help you better understand your disease and your treatment with Tracleer
- Tools such as journals and calendars to record your progress and help you remember key dates
One-on-one phone support
Sure Steps Nurse Counselors are trained nurses you can call for help finding answers to general questions about important topics such as:
- What to expect from your treatment with Tracleer
- Why monthly liver function and, if applicable, pregnancy testing is so important when on Tracleer
- Healthy living tips
- Why following your healthcare provider's instructions is so important
- How Sure Steps can help you and your caregivers
Sure Steps website access
The Sure Steps website provides you 24-7 access to the wealth of educational and motivational support available exclusively
to Tracleer patients enrolled in Sure Steps. Here you can learn more about your disease and treatment with Tracleer, and
you'll get on-demand access to information and resources to help you along your
treatment journey.
Sure Steps Connect access
Sure Steps Connect is a conference series that you can watch online. These educational conferences allow patients on
Tracleer and their caregivers to watch experts discuss a variety of PAH*- and Tracleer-related topics. At the end of each of
these live events, the speakers will take time to answer your questions.
Caregivers can take part in Sure Steps too!
At Sure Steps, we recognize the importance of caregivers and encourage them to participate.
Caregivers can:
- Get involved by speaking directly with Sure Steps Nurse Counselors
- Participate on the Sure Steps website
- Participate in Sure Steps Connect where they can see and talk with experts
|
To speak with a specially trained Sure Steps Nurse Counselor, please call:
- English 1-866-ACTELION (1-866-228-3546),
Mon.–Fri., 8 am–11 pm (ET).
- Español 1-877-783-7791
lunes–viernes 9 am–5 pm (Hora del Este).
|
*What is Tracleer?
Tracleer is a prescription medicine indicated for patients with certain types of pulmonary arterial hypertension (PAH), which is high blood pressure in the vessels of the lungs, (WHO Group 1). Tracleer can improve your ability to exercise as measured by 6-minute walk test and can slow the worsening of your physical condition and symptoms.
- In two different studies, Tracleer improved 6-minute walk distance by 35 and 76 meters. These studies focused on patients with WHO Functional Class III-IV.1
- Clinical worsening was defined as any one of the following: a need to go to the hospital for PAH, stopping treatment because of worsening of PAH, a need for intravenous (IV) treatment (epoprostenol), or death.1-3
Studies showing Tracleer is effective included mainly patients with NYHA Functional Class II-IV PAH. In these patients, PAH was caused by: unidentified or hereditary factors (60%); connective tissue disease (21%); being born with a hole in the heart between the left and right sides (18%).
In patients with WHO Functional Class II symptoms, Tracleer slowed the worsening of PAH, however, did not show meaningful improvement in walk distance. If you are a patient with WHO Functional Class II symptoms, your healthcare provider will consider whether the potential benefits of Tracleer outweigh the risk of liver damage, which may prevent future use of Tracleer as your disease progresses.
Tracleer is only:
- prescribed by healthcare providers who are enrolled in T.A.P.
- available to people who understand and agree to enroll in T.A.P.
It is not known if Tracleer is safe and works in children below 12 years of age.
What is the most important information I should know about Tracleer?
Tracleer is only available through the Tracleer Access Program (T.A.P.). Before you begin taking Tracleer, you must read and agree to all of the instructions in T.A.P. Because of potential liver damage and in an effort to make the chance of fetal exposure to Tracleer® (bosentan) as small as possible, Tracleer may be prescribed only through the Tracleer Access Program (T.A.P.), by calling 1-866-228-3546. Adverse events can also be reported directly via this number.
Liver damage:
- Liver damage may not cause symptoms at first. Only a blood test can show if you have early liver damage. So you must have a blood test to check your liver function before you start Tracleer and each month after that. Your healthcare provider will order these tests. Regular blood tests are important because they will help your healthcare provider adjust or stop your treatment before there is permanent damage.
- Tracleer can cause serious liver damage, including in rare cases liver failure. The contribution of Tracleer in these cases could not be excluded. Even in situations with regular liver testing, rare cases of unexplained liver cirrhosis (scar tissue in the liver) have developed in patients with other medical conditions and taking other medications in addition to Tracleer for over 12 months. Tell your healthcare provider if you have had liver problems, including liver problems while taking other medicines. Call your healthcare provider right away if you have any of these symptoms of liver problems while taking Tracleer: nausea, vomiting, fever, unusual tiredness, stomach area (abdominal) pain, or yellowing of the skin or the whites of your eyes (jaundice).
Serious birth defects:
- Tracleer can cause serious birth defects if taken during pregnancy. You must not be pregnant when you start taking Tracleer or during Tracleer treatment. Serious birth defects from Tracleer can happen early in pregnancy. Females who are able to get pregnant must have a negative pregnancy test before starting treatment and each month during Tracleer treatment.
- Talk with your healthcare provider or gynecologist (a doctor who specializes in female reproduction) to find out about how to prevent pregnancy. Do not have unprotected sex. Tell your healthcare provider right away if you miss a menstrual period or think you may be pregnant.
- Females who are able to get pregnant must use birth control (contraception) during Tracleer treatment. You must choose and use two reliable forms of birth control at the same time, unless you have had a tubal sterilization, or have a Copper T 380A IUD or LNg-20 IUS. These methods can be used alone.
- Talk with your healthcare provider about which 2 methods of reliable birth control you should use. Your healthcare provider may recommend that you use a different method of birth control to help lower your risk of problems with your pulmonary arterial hypertension.
Who should not take Tracleer?
Do not take Tracleer if you:
- Are pregnant, plan to become pregnant, or become pregnant during Tracleer treatment. Tracleer can cause serious birth defects. All females should read the birth defects section of "What is the most important information I should know about Tracleer?"
- Have a blood test that shows possible liver injury.
- Take one of these medicines:
| — | Do not take Tracleer with cyclosporine-A, a medication used for psoriasis and rheumatoid arthritis, and to prevent rejection of heart or kidney transplants. Using cyclosporine-A with Tracleer may increase your chance of side effects. |
| — | Do not take Tracleer with glyburide. Glyburide is used to treat diabetes and when used with Tracleer it may increase your chance of liver injury. |
- Are allergic to any of the ingredients in Tracleer. If you have a rash, hives or your lips swell after taking Tracleer, it may be a sign of an allergy. You should stop taking your Tracleer and talk to your healthcare provider.
What are the possible side effects of Tracleer?
Tracleer can cause serious side effects, including:
- See "What is the most important information I should know about Tracleer?"
- Fluid retention and swelling of ankles and legs. Tracleer can cause your body to hold too much water, and you may get swelling of your ankles and legs. Tell your healthcare provider if you have swelling of your ankles and legs that happens either with or without weight gain, or if you have more trouble with your breathing than normal. Your healthcare provider will look for the cause of this.
- Lower sperm count. Some men who take Tracleer may have lower sperm counts. This may affect your ability to father a child. Tell your healthcare provider if fertility is a concern for you.
- Low red blood cell levels (anemia). Your healthcare provider will do blood tests to check your red blood cells during treatment with Tracleer.
The most common side effects of Tracleer are: respiratory tract infection, headache, fainting, flushing, low blood pressure, inflamed nose passages (sinusitis), joint pain and irregular heartbeats.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Tracleer. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see full Prescribing Information and Medication Guide.
REFERENCES:
- TRACLEER® (bosentan) full Prescribing Information. Actelion Pharmaceuticals US, Inc., February 2011.
- Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903.
- Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.